Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment of dyslipidaemias in patients with established vascular disease:A revival of the fibrates
Autore:
Milionis, HJ; Elisaf, MS; Mikhailidis, DP;
Indirizzi:
Univ Coll London, Dept Mol Pathol & Clin Biochem, Royal Free & Univ Coll Med Sch, London NW3 2QG, England Univ Coll London London England NW3 2QG Med Sch, London NW3 2QG, England Univ Ioannina, Sch Med, Dept Internal Med, GR-45110 Ioannina, Greece Univ Ioannina Ioannina Greece GR-45110 al Med, GR-45110 Ioannina, Greece
Titolo Testata:
CURRENT MEDICAL RESEARCH AND OPINION
fascicolo: 1, volume: 16, anno: 2000,
pagine: 21 - 32
SICI:
0300-7995(2000)16:1<21:TODIPW>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY-ARTERY DISEASE; FAMILIAL COMBINED HYPERLIPIDEMIA; INSULIN-RESISTANCE SYNDROME; COA REDUCTASE INHIBITORS; LOW-DENSITY LIPOPROTEINS; HEART-DISEASE; MYOCARDIAL-INFARCTION; FOLLOW-UP; CHOLESTEROL LEVELS; PLASMA-FIBRINOGEN;
Keywords:
cholesterol; ciprofibrate; dyslipidaemia; fibrates; fibrinogen; high-density lipoprotein; ischaemic heart disease; lipoprotein (a); low-density lipoprotein; low-density lipoprotein subfractions; triglyceride;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
89
Recensione:
Indirizzi per estratti:
Indirizzo: Mikhailidis, DP Univ Coll London, Dept Mol Pathol & Clin Biochem, Royal Free & Univ Coll Med Sch, Royal Free Campus,Pond St, London NW3 2QG, England Univ Coll London Royal Free Campus,Pond St London England NW3 2QG
Citazione:
H.J. Milionis et al., "Treatment of dyslipidaemias in patients with established vascular disease:A revival of the fibrates", CURR MED R, 16(1), 2000, pp. 21-32

Abstract

The key 'statin trials' focussed on the beneficial effect of lowering the circulating concentrations of low-density lipoprotein cholesterol (LDL). However, epidemiological surveys, mainly based on healthy populations, indicate that other lipid-related variables, such as high-density cholesterol (HDL), triglycerides (TG), dense LDL subfraction distribution, and possibly lipoprotein (a) (Lp(a)), are also predictors of vascular events. Furthermore,TG and HDL levels influenced outcome within some of the statin trials. Plasma fibrinogen levels have also been shown to be powerful predictors of vascular risk in healthy subjects and patients with established ischaemic heart disease. The fibrates exert beneficial effects on all these variables that predict vascular events. The results from recent trials, the Bezafibrate Infarction Prevention (BIP) study and the Veterans Administration HDL Intervention Trial (VA-HIT) have revived our interest in fibrates. These trials involved bezafibrate and gemfibrozil that have a relatively poor LDL-lowering capacity. Therefore, the benefits reported in BIP and VA-HIT must be attributed to actions on variables other than a reduction in LDL quantity. Ciprofibrate and fenofibrate have significantly greater LDL-lowering capacity than bezafibrate or gemfibrozil. This advantage may render them more effective, especially since they retain the additional beneficial actions associated with this class of lipid-lowering drugs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 19:18:50